Brief: Inmune Bio Targets UK Maa In Q4 2026, EU Maa And US BLA In Q1 2027
26/08/2026 12:14
BRIEF-Inmune Bio Targets UK Maa In Q4 2026, EU Maa And US BLA In Q1 2027 Aug 26 (Reuters) - INmune Bio Inc INMB.O:
INMUNE BIO - COMPANY TARGETS UK MAA IN Q4 2026, EU MAA AND U.S. BLA IN Q1 2027
INMUNE BIO ADVANCES EBSTROCEL™ TOWARD EUROPEAN MARKETING AUTHORIZATION WITH EMA REGULATORY FILINGS
Source text: ID:nGNX8nKNJd
Further company coverage: INMB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inmune Bio
See all newsBrief: Inmune Bio - Enters Master Services Agreement With Uniphar For Ebstrocel International Commercialization
Brief: Inmune Bio Targets UK Maa In Q4 2026, EU Maa And US BLA In Q1 2027
INmune Bio Inc reports results for the quarter ended June 30 - Earnings Summary
INmune Bio Q2 net loss narrows on lower impairment charges
INmune Bio Inc expected to post a loss of 21 cents a share - Earnings Preview